Trial Outcomes & Findings for A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia (NCT NCT01394991)

NCT ID: NCT01394991

Last Updated: 2012-04-05

Results Overview

Clinically relevant and objectively confirmed thrombovascular event (TVE) was determined by the Adjudication Committee from randomization through Week 16. Clinically relevant TVEs were defined as deep vein thrombosis (DVT) of the limbs; thromboses of other major veins; pulmonary embolism (PE);acute coronary syndrome (ACS);ischemic stroke of arterial or cardiac origin; cerebral venous thrombosis; and arterial thrombosis. Objectively confirmed was defined as the confirmation of the clinical diagnosis of a TVE by appropriate medical imaging studies and laboratory tests.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

504 participants

Primary outcome timeframe

from randomization through Week 16

Results posted on

2012-04-05

Participant Flow

This is a randomized, open-label, multicenter study evaluating thrombovascular events in participants with cancer receiving chemotherapy and administered Epoetin Alfa once weekly (QW) or three times a week (TIW) for the treatment of anemia.

Participant milestones

Participant milestones
Measure
Epoetin Alfa QW
epoetin alfa at an initial dosage of 450 IU/kg once a week (QW)
Epoetin Alfa TIW
epoetin alfa at an initial dosage of 150 IU/kg 3 times a week (TIW)
Overall Study
STARTED
242
262
Overall Study
COMPLETED
183
190
Overall Study
NOT COMPLETED
59
72

Reasons for withdrawal

Reasons for withdrawal
Measure
Epoetin Alfa QW
epoetin alfa at an initial dosage of 450 IU/kg once a week (QW)
Epoetin Alfa TIW
epoetin alfa at an initial dosage of 150 IU/kg 3 times a week (TIW)
Overall Study
Adverse Event
0
4
Overall Study
Lack of Efficacy
5
7
Overall Study
Lost to Follow-up
6
8
Overall Study
Physician Decision
1
3
Overall Study
Protocol Violation
1
1
Overall Study
Withdrawal by Subject
20
17
Overall Study
Chemotherapy Termination
10
15
Overall Study
Disease Progression
7
7
Overall Study
Prematurely Termination of Trial
9
10

Baseline Characteristics

A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Epoetin Alfa QW
n=242 Participants
epoetin alfa at an initial dosage of 450 IU/kg once a week (QW)
Epoetin Alfa TIW
n=262 Participants
epoetin alfa at an initial dosage of 150 IU/kg 3 times a week (TIW)
Total
n=504 Participants
Total of all reporting groups
Age, Categorical
<=18 years
1 Participants
n=5 Participants
1 Participants
n=7 Participants
2 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
160 Participants
n=5 Participants
173 Participants
n=7 Participants
333 Participants
n=5 Participants
Age, Categorical
>=65 years
81 Participants
n=5 Participants
88 Participants
n=7 Participants
169 Participants
n=5 Participants
Age Continuous
58.8 years
STANDARD_DEVIATION 13.35 • n=5 Participants
57.5 years
STANDARD_DEVIATION 13.53 • n=7 Participants
58.1 years
STANDARD_DEVIATION 13.44 • n=5 Participants
Sex: Female, Male
Female
156 Participants
n=5 Participants
181 Participants
n=7 Participants
337 Participants
n=5 Participants
Sex: Female, Male
Male
86 Participants
n=5 Participants
81 Participants
n=7 Participants
167 Participants
n=5 Participants
Region of Enrollment
Bulgaria
6 participants
n=5 Participants
7 participants
n=7 Participants
13 participants
n=5 Participants
Region of Enrollment
France
7 participants
n=5 Participants
6 participants
n=7 Participants
13 participants
n=5 Participants
Region of Enrollment
Germany
51 participants
n=5 Participants
55 participants
n=7 Participants
106 participants
n=5 Participants
Region of Enrollment
Great Britain
1 participants
n=5 Participants
4 participants
n=7 Participants
5 participants
n=5 Participants
Region of Enrollment
Greece
8 participants
n=5 Participants
12 participants
n=7 Participants
20 participants
n=5 Participants
Region of Enrollment
Italy
13 participants
n=5 Participants
13 participants
n=7 Participants
26 participants
n=5 Participants
Region of Enrollment
Poland
7 participants
n=5 Participants
6 participants
n=7 Participants
13 participants
n=5 Participants
Region of Enrollment
Romania
21 participants
n=5 Participants
20 participants
n=7 Participants
41 participants
n=5 Participants
Region of Enrollment
Russia
88 participants
n=5 Participants
93 participants
n=7 Participants
181 participants
n=5 Participants
Region of Enrollment
Slovakia
9 participants
n=5 Participants
11 participants
n=7 Participants
20 participants
n=5 Participants
Region of Enrollment
Ukraine
31 participants
n=5 Participants
35 participants
n=7 Participants
66 participants
n=5 Participants

PRIMARY outcome

Timeframe: from randomization through Week 16

Population: The modified intent-to-treat (mITT) population was defined to include all randomized participants who received at least 1 dose of study drug.

Clinically relevant and objectively confirmed thrombovascular event (TVE) was determined by the Adjudication Committee from randomization through Week 16. Clinically relevant TVEs were defined as deep vein thrombosis (DVT) of the limbs; thromboses of other major veins; pulmonary embolism (PE);acute coronary syndrome (ACS);ischemic stroke of arterial or cardiac origin; cerebral venous thrombosis; and arterial thrombosis. Objectively confirmed was defined as the confirmation of the clinical diagnosis of a TVE by appropriate medical imaging studies and laboratory tests.

Outcome measures

Outcome measures
Measure
Epoetin Alfa QW
n=242 Participants
epoetin alfa at an initial dosage of 450 IU/kg once a week (QW)
Epoetin Alfa TIW
n=262 Participants
epoetin alfa at an initial dosage of 150 IU/kg 3 times a week (TIW)
Number of Participants With at Least 1 Clinically Relevant and Objectively Confirmed Thrombovascular Event From Randomization Through Week 16
5 particpants
10 particpants

SECONDARY outcome

Timeframe: during the study (randomization through week 26)

Population: The modified intent-to-treat (mITT) population used for safety analysis population included all randomized participants who received at least 1 dose of study drug.

The number of participants who have at least 1 clinically relevant and objectively confirmed (adjudicated) thrombovascular event (TVE) during the study.

Outcome measures

Outcome measures
Measure
Epoetin Alfa QW
n=242 Participants
epoetin alfa at an initial dosage of 450 IU/kg once a week (QW)
Epoetin Alfa TIW
n=262 Participants
epoetin alfa at an initial dosage of 150 IU/kg 3 times a week (TIW)
Number of Positively Adjudicated Thrombovascular Events
5 participants
13 participants

SECONDARY outcome

Timeframe: during the study (randomization through week 26)

Population: All randomized participants who received at least 1 dose of study drug.

Analysis of time to first positively adjudicated thrombovascular event (TVE) measured from the date of randomization to the date of the first clinically relevant and objectively confirmed TVE as determined by the Adjudication Committee. Median time is non-estimable because of too few events, incidence was reported instead.

Outcome measures

Outcome measures
Measure
Epoetin Alfa QW
n=242 Participants
epoetin alfa at an initial dosage of 450 IU/kg once a week (QW)
Epoetin Alfa TIW
n=262 Participants
epoetin alfa at an initial dosage of 150 IU/kg 3 times a week (TIW)
Time to First Positively Adjudicated Thrombovascular Event
5 participants
13 participants

SECONDARY outcome

Timeframe: during the study (randomization through week 26)

Population: All randomized participants who received at least 1 dose of study drug.

Number of participants who have at least 1 suspected thrombovascular events (TVEs) during the entire study. Suspected TVEs were defined as suspected TVEs during the entire study, whether clinically relevant and objectively confirmed by the Adjudication Committee or not, whether confirmed by the investigator or not.

Outcome measures

Outcome measures
Measure
Epoetin Alfa QW
n=242 Participants
epoetin alfa at an initial dosage of 450 IU/kg once a week (QW)
Epoetin Alfa TIW
n=262 Participants
epoetin alfa at an initial dosage of 150 IU/kg 3 times a week (TIW)
Number of Suspected Thrombovascular Events
9 participants
20 participants

SECONDARY outcome

Timeframe: during the study (randomization through week 26)

Population: All randomized participants who received at least 1 dose of study drug.

Analysis of time to first suspected thrombovascular event (TVE) measured from the date of randomization to the date of the first suspected TVE during the study. Median time is non-estimable because of too few events, incidence was reported instead.

Outcome measures

Outcome measures
Measure
Epoetin Alfa QW
n=242 Participants
epoetin alfa at an initial dosage of 450 IU/kg once a week (QW)
Epoetin Alfa TIW
n=262 Participants
epoetin alfa at an initial dosage of 150 IU/kg 3 times a week (TIW)
Time to First Suspected Thrombovascular Event
9 participants
20 participants

SECONDARY outcome

Timeframe: during the study (randomization through week 26)

Population: All randomized participants who received at least 1 dose of study drug.

Number of participants who died during the study.

Outcome measures

Outcome measures
Measure
Epoetin Alfa QW
n=242 Participants
epoetin alfa at an initial dosage of 450 IU/kg once a week (QW)
Epoetin Alfa TIW
n=262 Participants
epoetin alfa at an initial dosage of 150 IU/kg 3 times a week (TIW)
Mortality
25 participants
26 participants

SECONDARY outcome

Timeframe: during the study (randomization through week 26)

Population: All participants who were randomized, regardless of whether or not they received study drug.

Hemoglobin response was defined as a hemoglobin increase of ≥2 g/dL from baseline or reaching a hemoglobin concentration of 12 g/dL, regardless of dose adjustment.

Outcome measures

Outcome measures
Measure
Epoetin Alfa QW
n=242 Participants
epoetin alfa at an initial dosage of 450 IU/kg once a week (QW)
Epoetin Alfa TIW
n=262 Participants
epoetin alfa at an initial dosage of 150 IU/kg 3 times a week (TIW)
Number of Hemoglobin Responders
179 participants
187 participants

SECONDARY outcome

Timeframe: during the study (randomization through week 26)

Population: All participants who were randomized, regardless of whether or not they received study drug.

The number of participants who received at least 1 red blood cell (RBC) transfusion (packed RBC or whole blood) during the study.

Outcome measures

Outcome measures
Measure
Epoetin Alfa QW
n=242 Participants
epoetin alfa at an initial dosage of 450 IU/kg once a week (QW)
Epoetin Alfa TIW
n=262 Participants
epoetin alfa at an initial dosage of 150 IU/kg 3 times a week (TIW)
Red Blood Cell Transfusions
38 participants
42 participants

Adverse Events

Epoetin Alfa QW

Serious events: 53 serious events
Other events: 157 other events
Deaths: 0 deaths

Epoetin Alfa TIW

Serious events: 64 serious events
Other events: 151 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Epoetin Alfa QW
n=242 participants at risk
epoetin alfa at an initial dosage of 450 IU/kg once a week (QW)
Epoetin Alfa TIW
n=262 participants at risk
epoetin alfa at an initial dosage of 150 IU/kg 3 times a week (TIW)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm progression
7.9%
19/242
7.6%
20/262
Blood and lymphatic system disorders
Anaemia
1.7%
4/242
0.76%
2/262
Blood and lymphatic system disorders
Febrile neutropenia
1.7%
4/242
0.00%
0/262
Blood and lymphatic system disorders
Leukopenia
1.2%
3/242
0.38%
1/262
Blood and lymphatic system disorders
Neutropenia
0.83%
2/242
1.1%
3/262
Blood and lymphatic system disorders
Pancytopenia
0.83%
2/242
0.38%
1/262
Blood and lymphatic system disorders
Thrombocytopenia
0.41%
1/242
1.5%
4/262
Infections and infestations
Pneumonia
0.83%
2/242
3.4%
9/262
Infections and infestations
Abscess jaw
0.41%
1/242
0.00%
0/262
Infections and infestations
Bronchitis
0.41%
1/242
0.00%
0/262
Infections and infestations
Endocarditis
0.41%
1/242
0.00%
0/262
Infections and infestations
Escherichia urinary tract infection
0.41%
1/242
0.00%
0/262
Infections and infestations
Herpes zoster
0.41%
1/242
0.00%
0/262
Infections and infestations
Sepsis
0.41%
1/242
0.76%
2/262
Infections and infestations
Septic shock
0.41%
1/242
0.00%
0/262
Infections and infestations
Abdominal wall abscess
0.00%
0/242
0.38%
1/262
Infections and infestations
Bronchopneumonia
0.00%
0/242
0.38%
1/262
Infections and infestations
Erysipeloid
0.00%
0/242
0.38%
1/262
Infections and infestations
Gastrointestinal infection
0.00%
0/242
0.38%
1/262
Infections and infestations
Kidney infection
0.00%
0/242
0.38%
1/262
Infections and infestations
Pneumonia primary atypical
0.00%
0/242
0.38%
1/262
Infections and infestations
Pyelonephritis
0.00%
0/242
0.38%
1/262
Infections and infestations
Urinary tract infection
0.00%
0/242
0.38%
1/262
Vascular disorders
Deep vein thrombosis
1.2%
3/242
1.5%
4/262
Vascular disorders
Hypotension
0.41%
1/242
0.00%
0/262
Vascular disorders
Hypovolaemic shock
0.41%
1/242
0.00%
0/262
Vascular disorders
Thrombosis
0.41%
1/242
0.00%
0/262
Vascular disorders
Venous thrombosis
0.41%
1/242
0.76%
2/262
Vascular disorders
Venous thrombosis limb
0.41%
1/242
0.38%
1/262
Vascular disorders
Cardiovascular insufficiency
0.00%
0/242
0.38%
1/262
Vascular disorders
Peripheral arterial occlusive disease
0.00%
0/242
0.38%
1/262
Vascular disorders
Thrombophlebitis
0.00%
0/242
0.38%
1/262
Respiratory, thoracic and mediastinal disorders
Dyspnoea
0.83%
2/242
0.38%
1/262
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
0.41%
1/242
0.00%
0/262
Respiratory, thoracic and mediastinal disorders
Haemoptysis
0.41%
1/242
0.00%
0/262
Respiratory, thoracic and mediastinal disorders
Pleural effusion
0.41%
1/242
0.00%
0/262
Respiratory, thoracic and mediastinal disorders
Pneumothorax
0.41%
1/242
0.00%
0/262
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
0.41%
1/242
0.00%
0/262
Respiratory, thoracic and mediastinal disorders
Respiratory failure
0.41%
1/242
0.38%
1/262
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
0.00%
0/242
1.5%
4/262
Gastrointestinal disorders
Subileus
0.83%
2/242
0.00%
0/262
Gastrointestinal disorders
Vomiting
0.83%
2/242
0.38%
1/262
Gastrointestinal disorders
Ascites
0.41%
1/242
0.00%
0/262
Gastrointestinal disorders
Diarrhoea
0.41%
1/242
0.00%
0/262
Gastrointestinal disorders
Gastric ulcer haemorrhage
0.41%
1/242
0.00%
0/262
Gastrointestinal disorders
Mesenteric artery thrombosis
0.41%
1/242
0.00%
0/262
Gastrointestinal disorders
Abdominal pain lower
0.00%
0/242
0.38%
1/262
Gastrointestinal disorders
Constipation
0.00%
0/242
0.38%
1/262
Gastrointestinal disorders
Dysphagia
0.00%
0/242
0.38%
1/262
Gastrointestinal disorders
Ileus
0.00%
0/242
0.38%
1/262
Gastrointestinal disorders
Intestinal obstruction
0.00%
0/242
0.38%
1/262
Gastrointestinal disorders
Odynophagia
0.00%
0/242
0.38%
1/262
Gastrointestinal disorders
Oesophageal stenosis
0.00%
0/242
0.38%
1/262
Gastrointestinal disorders
Small intestinal obstruction
0.00%
0/242
0.38%
1/262
General disorders
General physical health deterioration
0.83%
2/242
0.38%
1/262
General disorders
Asthenia
0.41%
1/242
0.00%
0/262
General disorders
Fatigue
0.41%
1/242
0.00%
0/262
General disorders
Multi-organ failure
0.41%
1/242
0.00%
0/262
General disorders
Pyrexia
0.41%
1/242
0.38%
1/262
General disorders
Chest pain
0.00%
0/242
0.76%
2/262
General disorders
Death
0.00%
0/242
0.38%
1/262
General disorders
Localised oedema
0.00%
0/242
0.38%
1/262
General disorders
Pain
0.00%
0/242
0.38%
1/262
General disorders
Sudden cardiac death
0.00%
0/242
0.38%
1/262
Metabolism and nutrition disorders
Anorexia
0.41%
1/242
0.00%
0/262
Metabolism and nutrition disorders
Cachexia
0.41%
1/242
0.00%
0/262
Metabolism and nutrition disorders
Hyperkalaemia
0.41%
1/242
0.00%
0/262
Metabolism and nutrition disorders
Tumour lysis syndrome
0.41%
1/242
0.00%
0/262
Cardiac disorders
Cardiogenic shock
0.41%
1/242
0.00%
0/262
Cardiac disorders
Cardiopulmonary failure
0.41%
1/242
0.38%
1/262
Cardiac disorders
Angina pectoris
0.00%
0/242
0.38%
1/262
Cardiac disorders
Cardiac failure
0.00%
0/242
0.38%
1/262
Cardiac disorders
Congestive cardiomyopathy
0.00%
0/242
0.38%
1/262
Cardiac disorders
Myocardial infarction
0.00%
0/242
0.38%
1/262
Musculoskeletal and connective tissue disorders
Muscle spasms
0.41%
1/242
0.00%
0/262
Musculoskeletal and connective tissue disorders
Pain in extremity
0.41%
1/242
0.00%
0/262
Musculoskeletal and connective tissue disorders
Arthralgia
0.00%
0/242
0.38%
1/262
Immune system disorders
Hypersensitivity
0.41%
1/242
0.00%
0/262
Injury, poisoning and procedural complications
Drug toxicity
0.41%
1/242
0.00%
0/262
Injury, poisoning and procedural complications
Pubic rami fracture
0.00%
0/242
0.38%
1/262
Injury, poisoning and procedural complications
Stent occlusion
0.00%
0/242
0.38%
1/262
Nervous system disorders
Syncope
0.41%
1/242
0.00%
0/262
Nervous system disorders
Cerebrovascular accident
0.00%
0/242
0.76%
2/262
Nervous system disorders
Spinal cord compression
0.00%
0/242
0.38%
1/262
Renal and urinary disorders
Renal failure acute
0.41%
1/242
0.38%
1/262
Renal and urinary disorders
Hydronephrosis
0.00%
0/242
0.76%
2/262
Renal and urinary disorders
Renal failure
0.00%
0/242
0.38%
1/262
Congenital, familial and genetic disorders
Aplasia
0.00%
0/242
0.38%
1/262
Hepatobiliary disorders
Acute hepatic failure
0.00%
0/242
0.38%
1/262
Hepatobiliary disorders
Cholangitis
0.00%
0/242
0.38%
1/262

Other adverse events

Other adverse events
Measure
Epoetin Alfa QW
n=242 participants at risk
epoetin alfa at an initial dosage of 450 IU/kg once a week (QW)
Epoetin Alfa TIW
n=262 participants at risk
epoetin alfa at an initial dosage of 150 IU/kg 3 times a week (TIW)
Blood and lymphatic system disorders
Neutropenia
33.5%
81/242
27.5%
72/262
Blood and lymphatic system disorders
Thrombocytopenia
21.5%
52/242
20.6%
54/262
Blood and lymphatic system disorders
Leukopenia
21.1%
51/242
16.8%
44/262
Gastrointestinal disorders
Nausea
11.2%
27/242
15.3%
40/262
Gastrointestinal disorders
Diarrhoea
10.7%
26/242
3.8%
10/262
Gastrointestinal disorders
Vomiting
5.4%
13/242
9.2%
24/262
General disorders
Asthenia
8.7%
21/242
5.3%
14/262
General disorders
Fatigue
7.0%
17/242
6.1%
16/262
General disorders
Pyrexia
6.2%
15/242
6.9%
18/262
Metabolism and nutrition disorders
Anorexia
5.4%
13/242
4.2%
11/262
Respiratory, thoracic and mediastinal disorders
Dyspnoea
5.4%
13/242
2.7%
7/262

Additional Information

Clinical Development Team Lead

Johnson and Johnson PRD

Phone: 1 908 218 6097

Results disclosure agreements

  • Principal investigator is a sponsor employee Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.
  • Publication restrictions are in place

Restriction type: OTHER